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infections, although the incidence of symptomatic infections in the older age
classes does increase. The impact of the different assumptions used in the model
was in general limited. CONCLUSIONS: We conclude that over a wide range of
assumptions, an additional booster dose can reduce the incidence of pertussis in
the population.
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OBJECTIVES: To investigate doctors’ perceptions towards factors underlying irra-
tional prescribing practices in treatment of malaria in Pakistan.METHODS:A qual-
itative study with snowball sampling technique was used to identify nineteen
doctors working at hospitals in Islamabad and Rawalpindi. Semi-structured inter-
views were conducted with the doctors until the point of saturation was obtained.
The interviews, which were audio-taped and transcribed verbatim, were evaluated
by thematic content analysis and by other authors’ analysis. RESULTS: Thematic
content analysis identified three major themes and several subthemes: 1) Factors
responsible for irrational prescribing practices in treatment of malaria; 2) Lack of
implementation of standard malaria treatment guidelines in the country; and 3)
Strategies to improve irrational prescribing practices in treatment of malaria. All
the doctors agreed on lack of implementation of standard guidelines in treatment
of malaria while mixed responses were observed regarding factors influencing
rational prescribing. Influence of pharmaceutical industry and unsupervised poly-
therapy were cited as major determinants for irrational prescribing practices in
case of malaria. CONCLUSIONS: The findings suggest that the doctors in Pakistan
are aware of irrational prescribing practices and its consequences in treatment of
malaria but are facing significant barriers in terms of improving the current pre-
scribing practices. There is an urgent need to design strategies such as implemen-
tation of standard malaria treatment guidelines, revision of health policies and up
gradation of education and training of health players in order to improve the cur-
rent prescribing practices for antimalarials.
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OBJECTIVES: Every winter season an influenza epidemic occurs, although strength
and duration may vary. In 2006-2007 in Austria presumably 5% of the whole pop-
ulation fell sick while 21% of age 15 and above were vaccinated. The goal was to
build an agent based model to understand, model and simulate the progress of
influenza epidemics. METHODS: The agent based model simulates single persons
with an infection state (susceptible, infected with or without symptoms, resistant,
vaccinated). Based on the results of a wide European study (POLYMOD, EC-Project
SP22-CT-2004-502084) people have contacts in different places like housholds,
schools or workplaces. Transmissions are possible upon contacts, then a person is
infected for a while until he or she becomes resistant upon recovery. RESULTS: The
outbreak of the epidemic starts when a few people are initially infected while the
rest is susceptible or vaccinated. After some time the epidemic stops due to a larger
number of resistant and a smaller number of susceptible people. Since only 5% of
the population fall sick the situations at outbreak and at termination of the epi-
demic are similar and therefore it behaves very sensitive to parameter changes.
CONCLUSIONS: Some parameter changes in the model can be interpreted as inter-
ventions in reality. But usually the influenza does not react sensitive to interven-
tions. For example, an increase of the vaccination rate by 5% prevents an outbreak
of the epidemic in the model which is obviously not true. This insight has two
consequences: First, the influenza does not just spread and stop by transmission
and recovery of people. There must be one or more other impacts modulating
outbreaks like predestined people to fall sick or the climate. Second, without
knowledge of these impacts it is almost impossible to predict the effect of vacci-
nation strategies exactely.
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OBJECTIVES: In 1996, the Brazilian government implemented a universal access
program for anti-retroviral drugs to improve the treatment of HIV/AIDS. A recent
study showed $1.78 billion USD savings from the program compared to pricing in
the US. This study estimates the drug costs saved in 2010 by the program’s imple-
mentation compared to pricing in Canada and Australia. METHODS: Nationwide
drug distribution data and drug prices for the Brazilian government’s antiretroviral
access program were obtained for 2010 from the Ministry of Health data. Drug
prices for each drug were converted to daily dosage costs in US dollars. Comparable
government drug prices were obtained for Ontario, Canada and Australia. The
Brazilian, Canadian, and Australian unit drug costs were multiplied by the distri-
bution rates in Brazil to calculate and compare the cost of the Brazilian 2010 drug
distribution using the Brazilian and Canadian/Australian pricing rates. Any cost
savings to the Brazilian government were also calculated. The savings calculation
assumes that the Brazilian government has paid for all of the drugs distributed
regardless of patient utilization rates. Sensitivity analysis was conducted on the
distribution rates, pricing, and utilization rates. RESULTS: The Brazilian govern-
ment saved $448.1 million USD in and $403.1 million USD 2010 versus Canada and
Australia, respectively through its pricing program. The total cost of the drugs
distributed was $1.94 billion with the Brazilian pricing. This compares to $2.37bil-
lion and $2.41 billion dollars using Canadian and Australian pricing rates, respec-
tively. Sensitivity analysis found the results to be stable. CONCLUSIONS: Signifi-
cant costs savings have been realized by the Brazilian government through its drug
pricing program. These costs savings should be included as part of any analysis of
the overall impact of the program.
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OBJECTIVES: Childhood prevention programs are important and imperative public
health initiatives. However, prevention programs are often associated with consid-
erable investments. This budget impact analysis was undertaken to position the
Italian investment for a program to prevent respiratory syncytial virus (RSV) con-
sequences in high-risk infants using palivizumab. This prevention program is com-
pared to an existing immunization program in the Lombardy region of Italy: Hu-
man Papillomavirus Vaccine [Types 6, 11, 16, 18] (HPV), considered standard of
care. METHODS: Two budget impact models were developed to assess the impact
of two different programs on Regional Health Service (RHS) expenditure: the budget
impact of RSV prophylaxis program was compared with a non-prophylaxis pro-
gram, while the budget impact of HPV active prophylaxis was compared with a
non-prophylaxis approach. Only direct costs based on disease prevalence, and
program efficacy were included. The model includes RSV prophylaxis administra-
tion costs, RSV-related resource consumption (visits, long term sequelae) and RSV
hospitalization over one year; for HPV prevention program, one year prophylaxis
was assessed against 5 years disease costs due to the low incidence of HPV related
disease in 1 year. Eligible subjects were preterm and high-risk infants (as estab-
lished by national guidelines) for RVS program and all 12-year-old girls cohort for
HPV program. RESULTS: RSV prophylaxis expenditure was estimated at
€11,577,776 in the prophylaxis program arm versus €5,206,534 in the ‘without pro-
phylaxis program’ arm, while for HPV prevention program, vaccination program
expenditure (including vaccine cost) would be 13,068,025€ vs. 356,385€ in no-vac-
cine arm. The net budgetary impact was calculated at €6.4 million for RSV vs. €12.7
million for HPV vaccination. CONCLUSIONS: Considering the RHS perspective, the
budget impact of palivizumab had lower program costs and higher disease cost
offsets vs. HPV vaccination program, positioning its economic value well within the
parameters of cost-effective childhood prevention programs.
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OBJECTIVES: To investigate whether patient reported outcomes could detect dif-
ferences between H1N1 and seasonal influenza vaccinations on resource utilisa-
tion and time off work over a 26 week follow up period. METHODS: In this evalua-
tion, PROBE methodology consisting of a web-based system supplemented by
telephone reporting was used to collect naturalistic data from people who had
received an influenza vaccination during 2009-2010 season. People were recruited
through media advertising and awareness campaigns in public places and work
(West of Scotland). Data collection on day of immunisation, after 3 days, 8 days, 6
weeks, 12 weeks and 26 weeks. Data included baseline demographics, any side
effects following vaccination including the duration/ resource use and time off
work. RESULTS: A total of 1103 vaccine recipients participated in the evaluation.
Overall, 42% of respondents reported experiencing any side effect after vaccination
(excluding pain/discomfort at site of injection) with more people reporting a side
effect with H1N1 vaccination (45% versus 26% seasonal flu vaccination versus 42%
receiving both vaccines p0.001). However, there was no significant difference in
health service utilisation between the groups – 5.2% H1N1, 2.3% Seasonal, 5.5% both
vaccines p0.468. 4 (0.6%) people in the H1N1 only group received hospital treat-
ment, 1 (0.8%) in the seasonal only group and 2 (0.9%) receiving both vaccines. Time
off work (absenteeism), in relation to flu like symptoms, also showed no significant
difference between the groups – 1.7% H1N1, 1.9% Seasonal, 3.4% both vaccines
p0.486. CONCLUSIONS: This evaluation shows that the PROBE methodology
quickly and simply captured patient reported outcome information on resource
utilisation and absenteeism in a vaccinated population. People receiving the H1N1
vaccination alone were more likely to experience side effects than seasonal influ-
enza vaccination alone but this did not lead to a significant increase in resource
utilisation or time off work.
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